We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
- Authors
Simon, George R; Verschraegen, Claire F; Jänne, Pasi A; Langer, Corey J; Dowlati, Afshin; Gadgeel, Shirish M; Kelly, Karen; Kalemkerian, Gregory P; Traynor, Anne M; Peng, Guangbin; Gill, John; Obasaju, Coleman K; Kindler, Hedy L
- Abstract
Pemetrexed in combination with cisplatin is approved for the treatment of pleural mesothelioma and is active in malignant peritoneal mesothelioma (MPeM). Pemetrexed and gemcitabine are synergistic in preclinical models, but the activity of this combination in MPeM is unknown. This clinical study assessed safety and efficacy of pemetrexed plus gemcitabine in chemotherapy-naïve patients with MPeM.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 21, p3567
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.15.2868